News | News By Subject | News by Disease News By Date | Search News

Myasthenia Gravis News Articles

Get Our FREE
Industry eNewsletter
Top Breaking News

News from Around the Web

Press Releases
Catalyst Pharma (CPRX) Announces Poster Presentation Of Musk-MG Clinical Data At The 13th International Conference On Myasthenia Gravis And Related Disorders     5/10/2017
Argenx Reaches 50% Enrollment In Phase II Clinical Trial Of ARGX-113 In Myasthenia Gravis     5/4/2017
Catalyst Pharma (CPRX) Neuromuscular Drug Hits Goals In Study     3/15/2017
Catalyst Pharma (CPRX) Provides Update On Its Clinical Trial For Patients With Congenital Myasthenic Syndromes     12/8/2016
Catalyst Pharma (CPRX) Announces FDA Orphan Drug Designation Of Firdapse For The Treatment Of Myasthenia Gravis     9/6/2016
Alexion (ALXN) Release: New Data From Phase III REGAIN Study Of Eculizumab (Soliris) In Patients With Refractory Generalized Myasthenia Gravis (Gmg) Presented At ICNMD Annual Congress     7/7/2016
Catalyst Pharma (CPRX) Announces Agreement With FDA On Confirmatory Phase III Study Protocol For Firdapse In Lambert-Eaton Myasthenic Syndrome     6/13/2016
Alexion (ALXN) Announces Topline Results From Phase III REGAIN Study Of Eculizumab (SolirisĀ®) In Patients With Refractory Generalized Myasthenia Gravis (gMG)     6/6/2016
Myasthenia Gravis: Curavac Launches Phase 1b Study In Patients     2/9/2016
Catalyst Pharmaceuticals (CPRX) Announces Initiation Of Investigator-Sponsored Study Of Firdapse In Patients With Musk-Antibody Positive Myasthenia Gravis     2/8/2016
Catalyst Pharmaceuticals (CPRX) Completes NDA Submission To FDA For Firdapse For The Treatment Of Lambert-Eaton Myasthenic Syndrome And Congenital Myasthenic Syndromes     12/17/2015
IMPAX Labs (IPXL) Receives FDA Approval For Generic Version Of Mestinon Timespan Tablets, 180 Mg     9/17/2015
Alexion Pharmaceuticals Inc. (ALXN)'s Phase 2 Study of Eculizumab (Soliris(R)) in Patients with Severe and Refractory Generalized Myasthenia Gravis Presented at MGFA Annual Meeting     9/15/2011
Bayhill Therapeutics, Inc. Announces the Successful Clearance of an IND for BHT-3034 for the Treatment of Myasthenia Gravis     3/2/2011
Cytokinetics, Inc. (CYTK) Announces Opening of a Phase IIa "Evidence of Effect" Clinical Trial of CK-2017357 in Patients With Myasthenia Gravis     1/4/2011